{
  "abstract": "Background/Objectives: Chronic neuropathic pain imposes a substantial burden on patients and society, and opioids are unsuitable for long-term use due to their addictive potential. To overcome this limitation, we encapsulated bupivacaine in PLGA nanoparticles to achieve sustained-release analgesia with reduced systemic toxicity. Methods: The analgesic efficacy was evaluated in rat models of chronic compression of the dorsal root ganglion (CCD) and chronic constriction injury (CCI). Nanoparticles were characterized using scanning electron microscopy (SEM) for morphology and size, and X-ray diffraction (XRD) for dispersion. In vivo electrophysiological recordings, including action potentials from DRG neuronal somata and compound action potentials in the sciatic nerve, were performed to investigate peripheral analgesic mechanisms, while plasma bupivacaine concentrations were measured by high-performance liquid chromatography (HPLC). Results: Bupivacaine nanoparticles significantly alleviated mechanical pain in both CCD and CCI rats, but had no effect on thermal pain. They selectively inhibited C-fiber conduction without affecting A-fibers. Importantly, plasma bupivacaine levels remained well below the corresponding toxic thresholds, indicating a favorable safety profile. Conclusions: These findings suggest that bupivacaine-loaded PLGA nanoparticles represent a promising long-term therapeutic option for chronic neuropathic pain management.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Human Anatomy, Histology and Embryology, State Key Laboratory of Common Mechanism Research for Major Diseases, Neuroscience Center, Joint Laboratory of Anesthesia and Pain, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing 100005, China.",
    "Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.",
    "National Human Brain Bank for Development and Function, Beijing 100005, China.",
    "Chinese Institute for Brain Research, Beijing 102206, China."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Tao Wang",
      "orcid": "0000-0001-5521-0644"
    },
    {
      "affs": [
        1
      ],
      "name": "Keyun Tang",
      "orcid": "0000-0002-5128-2648"
    },
    {
      "affs": [
        0
      ],
      "name": "Fengrun Sun",
      "orcid": "0000-0002-1512-612X"
    },
    {
      "affs": [
        0
      ],
      "name": "Yujia Ma"
    },
    {
      "affs": [
        0
      ],
      "name": "Yehong Fang"
    },
    {
      "affs": [
        0
      ],
      "name": "Ning Yu"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Fan Liu",
      "orcid": "0000-0002-9481-0797"
    },
    {
      "affs": [
        0,
        2,
        3
      ],
      "name": "Chao Ma",
      "orcid": "0000-0003-1346-6961"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4t8dwjdj3vr2c.bib",
  "cited_by": 0,
  "doi": "10.3390/pharmaceutics18101226",
  "fulltext_url": "https://europepmc.org/articles/PMC13708572",
  "id": "4t8dwjdj3vr2c",
  "issns": [
    "1999-4923"
  ],
  "landing_url": "https://europepmc.org/article/MED/42942757",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2737|Pain Mechanisms and Treatments"
    ]
  ],
  "openalex": "W7214660261",
  "pdf_url": "https://europepmc.org/articles/PMC13708572?pdf=render",
  "pmcid": "PMC13708572",
  "pmid": "42942757",
  "published": "2026-09-27",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/4t8dwjdj3vr2c.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:22:24Z",
      "native_id": "MED:42942757",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42942757"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2737|Pain Mechanisms and Treatments",
      "subfield": "physiology"
    }
  ],
  "title": "Bupivacaine-Loaded PLGA Nanoparticles for Long-Term Management of Chronic Neuropathic Pain.",
  "title_text": "Bupivacaine-Loaded PLGA Nanoparticles for Long-Term Management of Chronic Neuropathic Pain.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:22:24Z",
  "url": "https://research.draconitic.com/paper/4t8dwjdj3vr2c",
  "venue": "Pharmaceutics",
  "versions": []
}